Skip to main content
//empty //empty
Coronavirus information
Coronavirus information
The Zero Canada Project provides resources to help you manage your health, your finances and your family life as Canada reopens.
Visit the hub

A man enters the Pfizer World Headquarters building in New York on Nov. 23, 2015.

Brendan McDermid/Reuters

U.S. drugmaker Pfizer Inc. said on Thursday that early data has helped it identify a drug candidate with the potential to help treat patients infected with the novel coronavirus.

It also finalized a plan to develop a coronavirus vaccine in partnership with German drugmaker BioNTech SE and said the companies hope to produce millions of vaccines by the end of 2020. The companies said they plan to start trials of the vaccine as early as this month.

Data from preclinical studies of a compound that was originally developed to treat SARS – a different coronavirus that caused a major epidemic in 2003 – shows its potential to treat patients with the new coronavirus, Pfizer research chief Mikael Dolsten told Reuters in an interview.

Story continues below advertisement

Pfizer said it will conduct additional preclinical studies of the drug and aims to begin trials in humans in the third quarter of 2020.

In addition, Pfizer said it plans to support studies to determine whether existing Pfizer medicines, including its rheumatoid arthritis drug Xeljanz, may provide benefits for those struggling with the COVID-19 respiratory illness caused by the coronavirus.

“Pfizer has mobilized resources and capabilities to address every single frontier of the COVID-19 pandemic,” Mr. Dolsten said.

More than a dozen large drugmakers, including Pfizer, have announced plans in recent months to develop vaccines and treatments for the coronavirus, although few if any are likely to reach patients in time to stem the current outbreak.

Reuters last month was first to report Pfizer’s planned collaboration with BioNTech on a vaccine based on messenger RNA technology.

Pfizer will pay BioNTech US$185-million upfront to develop the vaccine, with additional payments if certain milestones are achieved that could boost its total investment to nearly US$750-million, the companies said.

Pfizer will help manufacture any eventual product and said it aims produce hundreds of millions of vaccines next year.

Story continues below advertisement

The largest U.S. drugmaker also announced a five-point plan for confronting the virus that includes collaborating with outside companies and institutions on the research, development and manufacture of treatments.

Meanwhile, Pfizer will help fund a study into whether Xeljanz, which belongs to a class of drugs called JAK inhibitors and also treats the autoimmune disease ulcerative colitis, can help patients with pneumonia caused by COVID-19.

Rheumatoid arthritis treatments from other drugmakers that work differently than Xeljanz are also being studied as possible COVID-19 treatments.

Pfizer is also looking into the potential of other drugs that work on the immune system to help coronavirus patients, the company said.

The company is also working with the Liverpool School of Tropical Medicine on two studies to better understand the relationship between coronavirus and pneumonia, which plays a role in many deaths caused by the virus that attacks the lungs.

Pfizer will also publish a review of research into whether its antibiotic azithromycin, sold under the brand name Zithromax, can play a role in treating COVID-19.

Story continues below advertisement

Azithromycin has been used with the malaria drug hydroxychloroquine by some doctors after a French study suggested the combination might benefit some COVID-19 patients.

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Report an error
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies